Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2021

Dempke Wolfram C M, Reck Martin

Abstract excerpt

The transcription factor NRF2 (nuclear factor E2-related factor 2) (also known as nuclear factor, erythroid 2 like 2 [NFE2L2]) is the master regulator of cellular antioxidant responses. NRF2 is repressed by interaction with a redox-sensitive protein KEAP1 (Kelch-like ECH-associated protein 1). Dysregulation of KEAP1/NRF2 transcriptional activity has been associated with the pathogenesis of multiple diseases, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kelch-Like ECH-Associated Protein 1
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NF-E2-Related Factor 2

Share to Phenotype

Source

Identifiers

PMID: 34303275
DOI: 10.1016/j.lungcan.2021.07.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?PMID 34303275Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.Semantic proximity Read ↗

Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.Semantic proximity Read ↗

[Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].Semantic proximity Read ↗

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.Semantic proximity Read ↗

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisSemantic proximity Read ↗

NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of TumourigenesisSemantic proximity Read ↗

Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.Semantic proximity Read ↗

NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.Semantic proximity Read ↗

The involvement of NRF2 in lung cancer.Semantic proximity Read ↗

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.Semantic proximity Read ↗

Nrf2: bane or blessing in cancer?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.